PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8636342-9 1996 ACTH-induced reductions in PGF2alpha-induced increases in FAP in the fetal placental circulation were not inhibited by the nitric oxide synthase inhibitor, N omega-nitro-L-arginine (100 micromol/L; n = 5), the cyclooxygenase inhibitor indomethacin (3 micromol/L; n = 5), or a guanylate cyclase inhibitor LY83583(1 micromol/L; n = 5). Indomethacin 235-247 proopiomelanocortin Homo sapiens 0-4 9619376-3 1998 However, there is one previous study which reported that such an inhibitory action of indomethacin on ACTH secretion is mediated principally by a fast, rate-sensitive negative feedback effect of corticosterone which increases after indomethacin injection, rather than by a decrease in PG production. Indomethacin 86-98 proopiomelanocortin Homo sapiens 102-106 9619376-3 1998 However, there is one previous study which reported that such an inhibitory action of indomethacin on ACTH secretion is mediated principally by a fast, rate-sensitive negative feedback effect of corticosterone which increases after indomethacin injection, rather than by a decrease in PG production. Indomethacin 232-244 proopiomelanocortin Homo sapiens 102-106 9619376-5 1998 Although IL-1 beta-induced ACTH response was significantly suppressed by indomethacin given either 10 or 20 min before, the latter protocol led to a significantly greater inhibition of the hormonal response than the former. Indomethacin 73-85 proopiomelanocortin Homo sapiens 27-31 15837925-7 2005 Additionally, indomethacin, which inhibits cyclooxygenase, and thereby, prostaglandin release, prevented corticosterone release from the adrenal induced by both NP and ACTH, demonstrating that prostaglandins mediate acute corticosterone release. Indomethacin 14-26 proopiomelanocortin Homo sapiens 168-172 15613736-5 2004 The nicotine-induced increase in ACTH and corticosterone response was significantly supressed by piroxicam, and diminished by indomethacin, but was significantly augmented by L-NAME and L-NNA. Indomethacin 126-138 proopiomelanocortin Homo sapiens 33-37 15613736-14 2004 histamine- and HTMT, a histamine H(1)-agonist-induced ACTH and corticosterone response were significantly diminished by piroxicam and indomethacin, respectively. Indomethacin 134-146 proopiomelanocortin Homo sapiens 54-58 7824084-10 1994 Indomethacin, an inhibitor of prostaglandin (PG) synthesis, has been shown to block both the induction of CRH secretion by IL-1 beta from hypothalamic explants, as well as the ACTH response to intravenous IL-1 beta. Indomethacin 0-12 proopiomelanocortin Homo sapiens 176-180 7824084-12 1994 The ACTH response was abolished (p < 0.005) when a low dose of indomethacin (1 mg/kg i.v.) Indomethacin 66-78 proopiomelanocortin Homo sapiens 4-8 8396869-9 1993 Indomethacin abolished the AVP and ACTH responses to IL-1 beta, but potentiated the pressor and hypothermic responses and increased plasma ANP. Indomethacin 0-12 proopiomelanocortin Homo sapiens 35-39 2239430-7 1990 We have found that this monokine can act following its third ventricular injection to stimulate ACTH, PRL, and GH release and to inhibit TSH release, at least in part, by release of prostaglandins since indomethacin, an inhibitor of prostaglandin synthesis, produced a blockade of the responses except for those of ACTH. Indomethacin 203-215 proopiomelanocortin Homo sapiens 315-319 1662458-11 1991 ACTH stimulated the release of 6-keto-PGF1 alpha and the secretion of P from the luteal cells of both species, which was inhibited by indomethacin or ibuprofen, but ACTH did not alter the cAMP content of luteal cells. Indomethacin 134-146 proopiomelanocortin Homo sapiens 0-4 2161351-2 1990 The present results show that ACTH responses induced by intravenous injection of IL-1 alpha were suppressed by systemic pretreatment with indomethacin and that intrahypothalamic injection of PGE2 stimulates the secretion of ACTH. Indomethacin 138-150 proopiomelanocortin Homo sapiens 30-34 2559195-9 1989 Pre-treatment with INDO also inhibited the increase in the plasma concentrations of ACTH induced by I.V. Indomethacin 19-23 proopiomelanocortin Homo sapiens 84-88 2834174-6 1988 Pretreatment with indomethacin completely prevented the ACTH response induced by either iv or icv injection of IL-1 beta. Indomethacin 18-30 proopiomelanocortin Homo sapiens 56-60 2564680-11 1989 The cyclooxygenase inhibitor indomethacin nearly completely blocked the stimulatory effect of cachectin on release of GH and TSH from dispersed pituitary cells but had only a slight and nonsignificant attenuating effect on its ACTH-releasing action. Indomethacin 29-41 proopiomelanocortin Homo sapiens 227-231 197569-0 1977 Stimulation of ACTH secretion by indomethacin and reversal by exogenous prostaglandins. Indomethacin 33-45 proopiomelanocortin Homo sapiens 15-19 3040807-4 1987 Studies of the mechanism of suppression revealed (a) a classical opioid receptor is involved (suppression was antagonized by naloxone and was specific for the NH2 terminus of beta-END), (b) monocytes are the primary target cell for opioids (monocyte-depleted lymphocyte preparations showed little suppression), and (c) reactive oxygen intermediates (ROI) and prostaglandin E2 are important mediators (scavengers of ROI and indomethacin eliminated the suppression). Indomethacin 423-435 proopiomelanocortin Homo sapiens 175-183 3017465-7 1986 The effect of ACTH could be prevented by indomethacin. Indomethacin 41-53 proopiomelanocortin Homo sapiens 14-18 227205-0 1979 Effect of two prostaglandin synthesis inhibitors, indomethacin and acetylsalicylic acid, on plasma ACTH and cortisol levels in man. Indomethacin 50-62 proopiomelanocortin Homo sapiens 99-103 6289585-10 1982 Additional experiments in subjects treated with propranolol or indomethacin allowed the conclusion that the effect of ACTH on PRA and P-A II is not mediated by renal beta-adrenergic receptors, but perhaps (partially?) Indomethacin 63-75 proopiomelanocortin Homo sapiens 118-122 6291809-9 1982 Only in the last group, in which the prostaglandin cyclooxygenase inhibitor, indomethacin, was not given during the sodium depletion, did an exaggerated aldosterone response to ACTH occur (an increase of 468% compared with an increase of 182% during control, P less than 0.005). Indomethacin 77-89 proopiomelanocortin Homo sapiens 177-181 233680-3 1978 However, the area under the curve for plasma ACTH after iv injection of regular insulin (0.1 U/kg) was significantly decreased during indomethacin administration (control, 88.0 +/- 32.6 cm2, mean +/- sd; indomethacin, 47.6 +/- 23.1, P less than 0.01). Indomethacin 134-146 proopiomelanocortin Homo sapiens 45-49 233680-3 1978 However, the area under the curve for plasma ACTH after iv injection of regular insulin (0.1 U/kg) was significantly decreased during indomethacin administration (control, 88.0 +/- 32.6 cm2, mean +/- sd; indomethacin, 47.6 +/- 23.1, P less than 0.01). Indomethacin 204-216 proopiomelanocortin Homo sapiens 45-49 197569-1 1977 The prostaglandin (PG) synthesis inhibitor, indomethacin, has been found to enhance adrenocorticotropin (ACTH) secretion upon injection directly into the anterior pituitary at a dose that is ineffective intravenously. Indomethacin 44-56 proopiomelanocortin Homo sapiens 105-109 187409-5 1977 In this same preparation, indomethacin completely blocked ACTH and NPS-ACTH facilitated PGF2alpha and PGE2 release but failed to suppress steroid release markedly. Indomethacin 26-38 proopiomelanocortin Homo sapiens 58-62 183238-5 1976 Steroidogenic concentrations of ACTH (50-250muU) enhanced PGE and PGF release, and indomethacin suppressed the ACTH-facilitated release. Indomethacin 83-95 proopiomelanocortin Homo sapiens 111-115 187409-5 1977 In this same preparation, indomethacin completely blocked ACTH and NPS-ACTH facilitated PGF2alpha and PGE2 release but failed to suppress steroid release markedly. Indomethacin 26-38 proopiomelanocortin Homo sapiens 71-75